Some of BIT’s relevant & significant announcements as below
Oct 2010 - Phase II HCV Trial Commenced
Oct 2011 - HEPATITIS C PHASE 2A TRIAL POSITIVE RESULTS
Nov 2012 - Key Phase 2 HIV/HCV Trial Commenced
Dec 2012 - Biotron Completes Clinical Stage of HIV Clinical Trial
Oct 2013 - ANTIVIRAL ACTIVITY ENHANCED IN HIV/HCV GENOTYPE 3 PATIENTS
July 2014 - BIT225 Reverses HIV-Induced Impairment of the Immune System
Mar 2016 - Phase 2 Hepatitis C Trial Success -> But no commercial deal! Probably because the main drug Interferon was considered an inferior drug in the market by 2015 (due to patient’s poor tolerance to this drug) when the very delayed results of Biotron's HCV came out as successful but no Pharma wanted BIT225 for HCV treatment tested with Interferon.
Basically, the clinical result of HCV is actually a failure in the real world. Biotron said they will publish the full results later in 2016 in a scientific conference and “hope for a commercial deal, but brushed this failure under the carpet, kept marching ahead with HIV trials, then zika test and then Covid-19 trials and back to HIV again (and people forgot all about their old carrot).
Feb 2017 - Started Phase 2 HIV-1 Clinical Trial
Sep 2018 - Significant Immunological Outcomes in BIT225 HIV-1 Trial
Nov 2018 - PRESENTATION OF BIT225-009 HIV-1 PHASE 2 DATA
Oct 2020 - BIT225 HIV-1 Immunomodulatory Paper Published
This is when they started the trials for both HIV-1 and Covid-19.
Nov 2021 - COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS
March 2022 - BIT225 Effectiveness Against COVID-19 in Animals
Aug 2022 - BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
Sep 2022 - Bit225 Covid-19 Human Study Commenced
Oct 2022 - Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
- results for both these have been awaited since Sept 2023.
They have been saying the delay in result is due to the CRO ( contract research organisations) delaying due to Covid backlogs ( in 2024)
Since their inception in 2001, BIOTRON has been regularly receiving R&D funding of ~$1.5M almost every year since 2013,
Intermittent capital raising from Share holders.
Looks like their actual plan is not to benefit the investors, but rather keep their regular income flow and keep up their wealthy lifestyles at the expense of SH's hard earned money.
This company has been claiming about BIT225 being effective against HIV since 2009.
15 years later, they are yet to announce the results of a Phase 2 Human Clinical trial !?!?
Comparatively, Sofosbuvir (HCV drug) was discovered in 2007, Human clinical trials in 2010 and commercial deal done in 2011 - 4 to 5 years in total.
Fair chance 2016 March is going to be repeated - 'Trial successful result but no commercial deal'
23 years of existence, with no significant contribution to the medical field or the share holders, but only been a free loader on Tax payers money through R&D rebates and SH's money through CR.
If this time, the clinical results dont show value in terms of potential treatment or value to the shareholders, the company's intention is nothing but fraudulent and they need to be legally investigated.
